Final answer:
Hemolytic disease of the newborn (HDN) occurs when maternal anti-Rh antibodies destroy fetal Rh+ red blood cells, causing anemia. Rho(D) immune globulin is used to prevent HDN in Rh- women carrying Rh+ babies.
Step-by-step explanation:
Hemolytic disease of the newborn (HDN) is a condition where maternal anti-Rh antibodies cross the placenta and target fetal Rh+ red blood cells for destruction, causing anemia. This can occur when an Rh- woman carries an Rh+ baby to term. The first exposure to the baby's Rh+ cells typically happens during the last trimester of pregnancy or during delivery. To prevent HDN, Rho(D) immune globulin is given to the mother. This medication binds fetal Rh+ red blood cells in the mother's bloodstream, preventing her immune system from producing antibodies against them.